Our Magnetom Verio is the world’s first magnetic resonance imaging (MRI) system to combine 3-tesla ultra-high field technology with a patient-friendly 70-centimeter open bore. Based on our innovative Total imaging matrix (Tim) technology, the system provides excellent image quality, superior diagnostic quality and exceptional patient comfort. Another innovative system, our 1.5-tesla Magnetom Essenza scanner, was developed to allow small hospitals and doctors’ offices with limited budgets to offer a full range of imaging services. Priced well below conventional high-field systems of this type, the Magnetom Essenza is the most cost-effective factory-fresh 1.5-tesla MRI system on the market.
With groundbreaking innovations like our Magnetom Verio and Magnetom Essenza systems, we’re enhancing the quality of care while cutting costs. Our solutions are playing an important role in making high-quality, affordable healthcare a reality for growing numbers of people. Patient-oriented healthcare is the key to our success. Our offerings encompass diagnostic and therapeutic technologies, IT solutions (clinical information systems and knowledge-based applications) and molecular in-vitro and in-vivo technologies (genomics and proteomics) as well as consulting and services. Leveraging this unique and innovative portfolio, we optimize efficiencies across the entire healthcare continuum – from prevention, early detection and diagnosis to treatment, therapy and follow-up care.
Over the last few years, we’ve expanded our portfolio through targeted acquisitions. By acquiring Shared Medical Systems (healthcare IT) in 2000, CTI Molecular Imaging in 2005, Diagnostic Products Corporation (DPC) and Bayer Diagnostics in 2006, and Dade Behring in 2007, we’ve created the world’s first and only fully integrated diagnostics company combining imaging diagnostics, laboratory diagnostics and clinical IT under one roof.

Our innovative technologies for early diagnosis and treatment are optimizing patient outcomes.
Thank you for viewing Siemens' Annual Report 2007.
If you require further information, please contact us:
Telephone
+49 89 636-33032 (Press Office)
+49 89 636-32474 (Investor Relations)
Telefax
+49 89 636-30085 (Press Office)
+49 89 636-32830 (Investor Relations)